Xembify
Biological
Grifols USA, LLC
Total Payments
$6.2M
Transactions
20,890
Doctors
4,422
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $806,955 | 6,003 | 2,353 |
| 2023 | $1.0M | 6,079 | 2,244 |
| 2022 | $1.1M | 4,482 | 1,838 |
| 2021 | $3.0M | 2,376 | 1,106 |
| 2020 | $296,464 | 1,651 | 777 |
| 2019 | $23,590 | 299 | 278 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.6M | 354 | 57.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 571 | 19.4% |
| Consulting Fee | $639,869 | 183 | 10.3% |
| Food and Beverage | $493,205 | 18,997 | 7.9% |
| Travel and Lodging | $248,231 | 752 | 4.0% |
| Education | $59,970 | 18 | 1.0% |
| Honoraria | $1,040 | 15 | 0.0% |
Payments by Type
Research
$3.6M
354 transactions
General
$2.6M
20,536 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects and LoadingMaintenance Dosing in Treatment-Nave Subjects With Primary Immunodeficiency | Grifols Therapeutics LLC | $2.4M | 0 |
| A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects and LoadingMaintenance Dosing in Treatment-Nave Subjects With Primary Immunodeficiency | Grifols Biologicals LLC | $778,194 | 2 |
| A Multi-Center, Parallel, Double-Blinded, PlaceboControlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY plus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and RecurrentorSevereInfections Associated with B-cell Chronic Lymphocytic Leukemia | Grifols Biologicals LLC | $88,279 | 0 |
| A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naive Subjects With Primary Immunodeficiency | Grifols Biologicals LLC | $72,548 | 0 |
| A Multi-Center, Parallel, Double-Blinded, PlaceboControlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY plus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and RecurrentorSevereInfections Associated with B-cell Chronic Lymphocytic Leukemia | Grifols Therapeutics LLC | $68,268 | 0 |
| A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects and LoadingMaintenance Dosing in Treatment-Nave Subjects with Primary Immunodeficiency | Grifols Therapeutics LLC | $50,828 | 0 |
| A Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY Plus Standard Medical Treatment Compared to Placebo Plus Standard Medical Treatment to Prevent Infections in Patient | Grifols Therapeutics LLC | $36,452 | 0 |
| A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY plus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and Recurrent or Severe Infections Associated with Bcell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | Grifols Biologicals LLC | $18,393 | 0 |
| A Multicenter, Randomized, Cross-over, Open-label Study to Evaluate IGSC 20 Flexible Dosing Including Daily Push Dosing In Treatment-Experienced Subjects With Primary Immunodeficiency PI and Evaluation of LoadingMaintenance IGSC 20 in Treatment-Nave Subjects With PI | Grifols Biologicals LLC | $17,880 | 0 |
| A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naive Subjects With Primary Immunodeficiency | Grifols Therapeutics LLC | $10,563 | 0 |
| A Multi-center, Single-Sequexperienced Subjects and Loading/Mance, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Eintenance Dosing in Treatment-Naive Subjects With Primary Immunodeficiency | Grifols Biologicals LLC | $6,628 | 0 |
| A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Nave Subjects With Primary Immunodeficiency | Grifols Therapeutics LLC | $2,500 | 0 |
Top Doctors Receiving Payments for Xembify — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pulmonary Disease | Butler, PA | $5,027 | 7 |
| , D.O | Allergy & Immunology | Omaha, NE | $4,926 | 19 |
| , MD | Allergy & Immunology | Gainesville, FL | $4,824 | 4 |
| , MS MD PHD | Allergy & Immunology | Cleveland, OH | $4,490 | 9 |
| , M.D | Allergy | Western Springs, IL | $4,410 | 4 |
| , MD | Internal Medicine | Pittsburgh, PA | $4,130 | 7 |
| , MD | Pediatric Allergy/Immunology | New Orleans, LA | $3,795 | 4 |
| , MD | Allergy & Immunology | Ft Lauderdale, FL | $3,473 | 6 |
| , M.D | Critical Care Medicine | Chicago, IL | $3,272 | 7 |
| , M.D | Allergy & Immunology | Springfield, IL | $3,112 | 9 |
| , M.D | Specialist | Suffern, NY | $3,022 | 24 |
| , D.O | Critical Care Medicine | Port Saint Lucie, FL | $2,964 | 12 |
| , M.D | Pulmonary Disease | Lakeland, FL | $2,901 | 4 |
| , M.D | Specialist | Greenfield, WI | $2,863 | 4 |
| , MD, MBA | Pediatrics | Aurora, CO | $2,863 | 4 |
| , MD | Allergy | Arlington, VA | $2,863 | 4 |
| , M.D | Allergy | Corning, NY | $2,846 | 27 |
| , M.D | Pediatric Hematology-Oncology | Cincinnati, OH | $2,810 | 7 |
| , M.D | Allergy & Immunology | Florham Park, NJ | $2,802 | 11 |
| , M.D | Pulmonary Disease | Rochester, MN | $2,800 | 1 |
| , MD | Critical Care Medicine | Phoenix, AZ | $2,732 | 4 |
| , M.D., PH.D | Hematology & Oncology | Cleveland, OH | $2,700 | 1 |
| , M.D | Pulmonary Disease | Weston, FL | $2,643 | 4 |
| , MD | Internal Medicine | Riverdale, GA | $2,639 | 13 |
| , NP-C | Family | Hershey, PA | $2,612 | 6 |
Ad
Manufacturing Companies
- Grifols USA, LLC $2.6M
- Grifols Therapeutics LLC $2.6M
- Grifols Biologicals LLC $981,920
- Grifols Shared Services North America, Inc. $11,130
Product Information
- Type Biological
- Total Payments $6.2M
- Total Doctors 4,422
- Transactions 20,890
About Xembify
Xembify is a biological associated with $6.2M in payments to 4,422 healthcare providers, recorded across 20,890 transactions in the CMS Open Payments database. The primary manufacturer is Grifols USA, LLC.
Payment data is available from 2019 to 2024. In 2024, $806,955 was paid across 6,003 transactions to 2,353 doctors.
The most common payment nature for Xembify is "Unspecified" ($3.6M, 57.4% of total).
Xembify is associated with 12 research studies, including "A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects and LoadingMaintenance Dosing in Treatment-Nave Subjects With Primary Immunodeficiency" ($2.4M).